Ocular gene therapy

John Campbell, Trevor J. Mcfarland, J. Timothy Stout

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Ocular gene therapy involves the introduction of an exogenous gene product to a host's cellular and genetic machinery for endogenous production of a desired gene product. The eye represents an ideal target organ due to its easy visibility and accessibility, and several trials have demonstrated proof-of-principle safety and efficacy in a subtype of Leber's congenital amaurosis. There are numerous ongoing clinical trials exploring gene therapy in other retinal diseases. In autosomal recessively inherited retinal degenerations, the introduced gene product replaces a known genetically deficient gene product and provides restoration of function. In other disease states, such as neovascular age-related macular degeneration, the delivered gene product modulates existing proteins within a cell, such as vascular endothelial growth factor, for a desired therapeutic effect. This latter approach may have broader applications in other diseases such as diabetes and other retinal vascular diseases that are as yet unrealized. This review summarizes the current state of clinical research in ocular gene therapy focusing on those diseases in which the technology has reached clinical trials.

Original languageEnglish (US)
Pages (from-to)317-321
Number of pages5
JournalDevelopments in Ophthalmology
Volume55
DOIs
StatePublished - 2015

Fingerprint

Genetic Therapy
Retinal Diseases
Genes
Leber Congenital Amaurosis
Clinical Trials
Retinal Vessels
Retinal Degeneration
Macular Degeneration
Therapeutic Uses
Vascular Diseases
Vascular Endothelial Growth Factor A
Technology
Safety
Research
Proteins

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Ocular gene therapy. / Campbell, John; Mcfarland, Trevor J.; Stout, J. Timothy.

In: Developments in Ophthalmology, Vol. 55, 2015, p. 317-321.

Research output: Contribution to journalArticle

Campbell, J, Mcfarland, TJ & Stout, JT 2015, 'Ocular gene therapy', Developments in Ophthalmology, vol. 55, pp. 317-321. https://doi.org/10.1159/000434698
Campbell, John ; Mcfarland, Trevor J. ; Stout, J. Timothy. / Ocular gene therapy. In: Developments in Ophthalmology. 2015 ; Vol. 55. pp. 317-321.
@article{ace0383a79014aeca42eff5dd9302e39,
title = "Ocular gene therapy",
abstract = "Ocular gene therapy involves the introduction of an exogenous gene product to a host's cellular and genetic machinery for endogenous production of a desired gene product. The eye represents an ideal target organ due to its easy visibility and accessibility, and several trials have demonstrated proof-of-principle safety and efficacy in a subtype of Leber's congenital amaurosis. There are numerous ongoing clinical trials exploring gene therapy in other retinal diseases. In autosomal recessively inherited retinal degenerations, the introduced gene product replaces a known genetically deficient gene product and provides restoration of function. In other disease states, such as neovascular age-related macular degeneration, the delivered gene product modulates existing proteins within a cell, such as vascular endothelial growth factor, for a desired therapeutic effect. This latter approach may have broader applications in other diseases such as diabetes and other retinal vascular diseases that are as yet unrealized. This review summarizes the current state of clinical research in ocular gene therapy focusing on those diseases in which the technology has reached clinical trials.",
author = "John Campbell and Mcfarland, {Trevor J.} and Stout, {J. Timothy}",
year = "2015",
doi = "10.1159/000434698",
language = "English (US)",
volume = "55",
pages = "317--321",
journal = "Developments in Ophthalmology",
issn = "0250-3751",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Ocular gene therapy

AU - Campbell, John

AU - Mcfarland, Trevor J.

AU - Stout, J. Timothy

PY - 2015

Y1 - 2015

N2 - Ocular gene therapy involves the introduction of an exogenous gene product to a host's cellular and genetic machinery for endogenous production of a desired gene product. The eye represents an ideal target organ due to its easy visibility and accessibility, and several trials have demonstrated proof-of-principle safety and efficacy in a subtype of Leber's congenital amaurosis. There are numerous ongoing clinical trials exploring gene therapy in other retinal diseases. In autosomal recessively inherited retinal degenerations, the introduced gene product replaces a known genetically deficient gene product and provides restoration of function. In other disease states, such as neovascular age-related macular degeneration, the delivered gene product modulates existing proteins within a cell, such as vascular endothelial growth factor, for a desired therapeutic effect. This latter approach may have broader applications in other diseases such as diabetes and other retinal vascular diseases that are as yet unrealized. This review summarizes the current state of clinical research in ocular gene therapy focusing on those diseases in which the technology has reached clinical trials.

AB - Ocular gene therapy involves the introduction of an exogenous gene product to a host's cellular and genetic machinery for endogenous production of a desired gene product. The eye represents an ideal target organ due to its easy visibility and accessibility, and several trials have demonstrated proof-of-principle safety and efficacy in a subtype of Leber's congenital amaurosis. There are numerous ongoing clinical trials exploring gene therapy in other retinal diseases. In autosomal recessively inherited retinal degenerations, the introduced gene product replaces a known genetically deficient gene product and provides restoration of function. In other disease states, such as neovascular age-related macular degeneration, the delivered gene product modulates existing proteins within a cell, such as vascular endothelial growth factor, for a desired therapeutic effect. This latter approach may have broader applications in other diseases such as diabetes and other retinal vascular diseases that are as yet unrealized. This review summarizes the current state of clinical research in ocular gene therapy focusing on those diseases in which the technology has reached clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84947209870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947209870&partnerID=8YFLogxK

U2 - 10.1159/000434698

DO - 10.1159/000434698

M3 - Article

C2 - 26502313

AN - SCOPUS:84947209870

VL - 55

SP - 317

EP - 321

JO - Developments in Ophthalmology

JF - Developments in Ophthalmology

SN - 0250-3751

ER -